Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109924 | 0.94 | IDO1 (0.54) | IDO1AGXTMAOBUSP2GAA | |
| SCHEMBL4995796 | 0.79 | IDO1 (0.64) | IDO1AGXTMAOBUSP2GAA | |
| SCHEMBL8995755 | 0.77 | IDO1 (0.61) | IDO1AGXTMAOBUSP2GAA | |
| SCHEMBL5977520 | 0.77 | IDO1 (0.50) | IDO1AGXTMAOBUSP2GAA | |
| SCHEMBL14420303 | 0.76 | PPARG (0.49) | IDO1AGXTMAOBPPARGPPARA | |
| SCHEMBL11711978 | 0.75 | MAOB (0.52) | IDO1AGXTMAOBCYP1A2 | |
| SCHEMBL357428 | 0.74 | IDO1 (0.64) | IDO1AGXTMAOBAPPMAOA | |
| SCHEMBL13378275 | 0.74 | IDO1 (0.52) | IDO1AGXTMAOBPPARGPPARA | |
| SCHEMBL5975337 | 0.73 | IDO1 (0.47) | IDO1AGXTMAOBUSP2GAA | |
| SCHEMBL11334466 | 0.73 | PPARG (0.54) | IDO1AGXTPPARGPPARARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292611-B1 | GLYCOPEPTIDE CARBOXY-SACCHARIDE DERIVATIVES | THERAVANCE INC (US) | 2008-03-12 | — | — | EP | disclosed |
| US-7244705-B2 | Polyacid glycopeptide derivatives | THERAVANCE, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20060194716-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-08-31 | — | — | US | disclosed |
| US-7074760-B2 | Polyacid glycopeptide derivatives | THERAVANCE, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050164919-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-07-28 | — | — | US | disclosed |
| US-6906031-B2 | Polyacid glycopeptide derivatives | THERAVANCE, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-6770621-B2 | GLYCOPEPTIDE WITH TWO OR MORE CARBOXY GROUPS AT THE C-TERMINUS, NOT INCLUDING SPECIFIED TEICOPLANINS; TREATING BACTERIAL DISEASES | THERAVANCE, INC. | 2004-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164919-A1 | Polyacid glycopeptide derivatives | B3GAT3, NGLY1, DNPEP | IDO1 3837/4885AGXT 209/4885MAOB 4327/4885 |
| US-20060194716-A1 | Polyacid glycopeptide derivatives | B3GAT3, NGLY1, DNPEP | IDO1 3837/4885AGXT 209/4885MAOB 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.